An analyst from Master Capital Services said that Bank of India has taken strong support at its long-term horizontal support ...

Laurus Labs latest update leaves the fair value estimate at roughly ₹821.93 per share with a steady discount rate of 12.76%, underscoring that the market narrative is shifting more on expectations ...

Hyderabad: Laurus Bio, a subsidiary of Hyderabad-based biopharma player Laurus Labs Ltd, has secured an equity investment of Rs 120 crore from Eight Roads Ventures and F-Prime Capital. Laurus Labs ...

Laurus Labs API segment is also well set to clock strong growth backed by the company’s increasing focus to diversify into new therapy areas - anti-diabetes and cardiology along with an eye to gain a ...

Revenue: INR1,570 crores, reflecting a 31% year-on-year growth. Gross Margin: 59%, an increase of more than 4% due to better product mix and process improvements. EBITDA: INR389 crores with a margin ...

Laurus Labs rallies to 52-week high after strong Q1, but analysts remain cautious with downside risk of up to 33 per cent. Laurus Labs has gained 18.36 per cent in the past month. Shares of Laurus ...

Laurus Labs has received a tentative nod from the Food and Drug Administration for Dolutegravir 5 mg and 10 mg for pediatric ARV treatment. This pediatric drug administration through oral dispersible ...

LAURUS LABS LTD - Board Meeting Intimation for Inter-Alia To Consider The Un-Audited Financial Results Of The Company For The ...